Inhibitors of short-chain dehydrogenase activity for treating coronary disorders

Abstract

A method of treating preventing, minimizing, and/or reversing congestive heart failure, cardiomyopathy, and/or reduction of cardiac ejection fraction in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

1 - 26 . (canceled) 
     
     
         27 : A method of treating cardiotoxicity in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor. 
     
     
         28 : The method of  claim 27 , wherein the cardiotoxicity includes a reduction of cardiac ejection fraction of at least about 10% and the 15-PGDH inhibitor is administered to the subject at an amount effective to increase cardiac ejection fraction by at least 10%. 
     
     
         29 : The method of  claim 28 , wherein the subject has or is at risk of hypertension. 
     
     
         30 : The method of  claim 27 , wherein the cardiotoxicity is induced by treatment of the subject with a cardiotoxic agent. 
     
     
         31 : The method of  claim 30 , wherein the cardiotoxic agent is a chemotherapeutic. 
     
     
         32 : The method of  claim 30 , wherein the cardiotoxic agent is selected from doxorubicin, epirubicin, daunorubicin, idarubicin, valrubicin, pirarubicin, amrubicin, aclarubicin, zorubicin, an anti-ErB2 or an anti-HER2 antibody. 
     
     
         33 : A method of treating a cardiomyopathy and/or a reduction of cardiac ejection fraction resulting from hypertension or cardiotoxicity in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor. 
     
     
         34 : The method of  claim 33 , wherein the cardiomyopathy and/or reduction of cardiac ejection fraction is induced by treatment of the subject with a cardiotoxic agent. 
     
     
         35 : The method of  claim 34 , wherein the cardiotoxic agent is a chemotherapeutic. 
     
     
         36 : The method of  claim 35 , wherein the cardiotoxic agent is selected from doxorubicin, epirubicin, daunorubicin, idarubicin, valrubicin, pirarubicin, amrubicin, aclarubicin, zorubicin, an anti-ErB2 or an anti-HER2 antibody. 
     
     
         37 : The method of  claim 33 , wherein the subject has or is at risk of hypertension.